Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.

CONTEXT Androgen excess may be adrenal and/or ovarian in origin; we hypothesized that a subgroup of patients with polycystic ovarian syndrome (PCOS) may have some degree of abnormal adrenocortical function. OBJECTIVE The objective of the study was to evaluate the pituitary adrenal axis with an oral low- and high-dose dexamethasone-suppression test (Liddle's test) in women with PCOS. DESIGN This was a case-control study. SETTING The study was conducted at the National Institutes of Health Clinical Center. PARTICIPANTS A total of 38 women with PCOS and 20 healthy volunteers (HV) aged 16-29 years participated in the study. MAIN OUTCOME MEASURES Urinary free cortisol (UFC) and 17-hydroxysteroids (17OHS) before and after low- and high-dose dexamethasone and assessment of adrenal volume by computed tomography scan were measured. RESULTS Twenty-four-hour urinary 17OHS and UFC were measured during day 1 to day 6 of the Liddle's test. Baseline UFC levels were not different between PCOS and HVs; on the day after the completion of high-dose dexamethasone administration (d 6), UFC was higher in the PCOS group (2.0 ± 0.7 μg/m(2)·d) than the HV group (1.5 ± 0.5) (P = .038). On day 5, 17OHS and UFC were negatively correlated with adrenal volumes (left side, rp = -0.47, P = .009, and rp = -0.61, P < .001, respectively). PCOS patients above the 75th percentile for UFC and/or 17OHS after high-dose dexamethasone (n = 15) had a significantly smaller total adrenal volume (6.9 ± 1.9 cm(3) vs 9.2 ± 1.8 cm(3), P = .003) when compared with the remaining PCOS patients (n = 22), but they did not have worse insulin resistance or hyperandrogenism. CONCLUSIONS In a subset of young women with PCOS, we detected a pattern of glucocorticoid secretion that mimicked that of patients with micronodular adrenocortical hyperplasia: they had smaller adrenal volumes and higher steroid hormone secretion after dexamethasone compared with the group of PCOS with appropriate response to dexamethasone.

[1]  R. Cobin,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  M. Murad,et al.  Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline , 2013, The Journal of clinical endocrinology and metabolism.

[3]  R. Azziz,et al.  Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome. , 2013, Fertility and sterility.

[4]  I. Bozic,et al.  Hypothalamic-pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome. , 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[5]  E. Littlejohn,et al.  Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. , 2011, Human reproduction.

[6]  W. Dodson,et al.  Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. , 2011, Fertility and sterility.

[7]  J. Bertherat,et al.  Cushing's Syndrome and Fetal Features Resurgence in Adrenal Cortex–Specific Prkar1a Knockout Mice , 2010, PLoS genetics.

[8]  Jacques Young,et al.  The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. , 2009, The Journal of clinical endocrinology and metabolism.

[9]  Stratakis Ca.  Adrenocortical Tumors, Primary Pigmented Adrenocortical Disease (PPNAD)/Carney Complex, and other Bilateral Hyperplasias: The NIH Studies , 2007 .

[10]  C. Stratakis.  Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[11]  B. Walker,et al.  Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome , 2006 .

[12]  B. Walker,et al.  Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  P. White.  Genotypes at 11β-Hydroxysteroid Dehydrogenase Type 11B1 and Hexose-6-Phosphate Dehydrogenase Loci Are Not Risk Factors for Apparent Cortisone Reductase Deficiency in a Large Population-Based Sample , 2005 .

[14]  J. L. San Millán,et al.  A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[15]  P. White.  Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. , 2005, Journal of Clinical Endocrinology and Metabolism.

[16]  R. Azziz,et al.  Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. , 2004, Fertility and sterility.

[17]  R. Azziz,et al.  Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. , 2004, Fertility and sterility.

[18]  W. Schürch,et al.  Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  S. Chew,et al.  The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. , 2003, The Journal of clinical endocrinology and metabolism.

[20]  B. Rich,et al.  Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  J. Martens,et al.  Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  D. Papanicolaou,et al.  Paradoxical Response to Dexamethasone in the Diagnosis of Primary Pigmented Nodular Adrenocortical Disease , 1999, Annals of Internal Medicine.

[23]  M. Güven,et al.  Glucocorticoid receptors on mononuclear leukocytes in polycystic ovary syndrome , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  R. Azziz,et al.  Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. , 1998, The Journal of clinical endocrinology and metabolism.

[25]  R. Azziz,et al.  Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  D. London,et al.  The hypothalamo‐pituitary‐adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome , 1993, Clinical endocrinology.

[27]  D. Ehrmann,et al.  Detection of functional ovarian hyperandrogenism in women with androgen excess. , 1992, The New England journal of medicine.

[28]  B. Wajchenberg,et al.  Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test. , 1986, The Journal of clinical endocrinology and metabolism.

[29]  P. Smyth,et al.  Adrenal Abnormalities in Polycystic Ovary Syndrome , 1986, The Journal of clinical endocrinology and metabolism.

[30]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[31]  R. Lobo,et al.  The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. , 1984, Fertility and sterility.

[32]  S. Yen,et al.  Adrenal function in normal women and women with the polycystic ovary syndrome. , 1979, The Journal of clinical endocrinology and metabolism.

[33]  M. Kirschner,et al.  Combined ovarian and adrenal vein catheterization to determine the site(s) of androgen overproduction in hirsute women. , 1971, The Journal of clinical endocrinology and metabolism.